<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report (Date of earliest event
reported): <U>April 18, 2012</U></B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SeraCare Life Sciences, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact Name of Registrant as Specified
in Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Delaware</B></P></TD>
    <TD STYLE="width: 5%; padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>001-34105</B></P></TD>
    <TD STYLE="width: 5%; padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>33-0056054</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation) </B></P></TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; font-weight: bold; text-align: center">(Commission file number)</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>37 Birch Street, Milford, Massachusetts
01757</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <U>(508) 244-6400</U>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Not Applicable</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="background-color: white"><B>Item 2.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white"><B>Completion of
Acquisition or Disposition of Assets.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At a special meeting of stockholders held
on April 18, 2012 (the &ldquo;Special Meeting&rdquo;), the stockholders of SeraCare Life Sciences, Inc., a Delaware corporation
(the &ldquo;Company&rdquo;), adopted the Agreement and Plan of Merger dated as of February 12, 2012 (as amended, the &ldquo;Merger
Agreement&rdquo;) by and among the Company, Project Plasma Holdings Corporation, a Delaware corporation (&ldquo;Parent&rdquo;),
and Project Plasma Merger Corp., a Delaware corporation and a wholly owned subsidiary of Parent (&ldquo;Merger Sub&rdquo;), and
the merger contemplated thereby (the &ldquo;Merger&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 20, 2012, the Company filed a certificate
of merger with the Secretary of State of the State of Delaware and completed the Merger, pursuant to which Merger Sub merged with
and into the Company, resulting in the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
Parent is controlled by private equity funds associated with Linden Capital Partners (&ldquo;Linden&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of the Merger, each share of
the Company&rsquo;s common stock issued and outstanding immediately prior to the effective time of the Merger (other than shares
(i) held by the Company in treasury, (ii) owned by Parent or Merger Sub or any other wholly owned subsidiary of Parent, or (iii)
held by stockholders who had perfected and not withdrawn a demand for appraisal rights under Delaware law) was cancelled and converted
automatically into the right to receive $4.00 in cash (the &ldquo;Per Share Merger Consideration&rdquo;), without interest. In
addition, at the effective time (a) each outstanding share of the Company&rsquo;s common stock subject to a risk of forfeiture
or a right of repurchase (&ldquo;restricted stock&rdquo;) was vested in full and became free of such restrictions, and was cancelled
and extinguished and automatically converted into the right to receive the Per Share Merger Consideration, without interest, and
(b) each outstanding option to acquire the Company&rsquo;s common stock with an exercise price less than $4.00 per share was cancelled
and converted automatically into the right to receive an amount in cash equal to the excess of $4.00 over the per share exercise
price of the stock option, for each share for which the option would have been exercisable. The total amount of the consideration
payable in connection with the Merger, including with respect to restricted stock and stock options, is approximately $82.1 million
in cash. The funds used by Parent to consummate the Merger are from equity contributions by private equity funds affiliated with
Linden, proceeds from debt financing provided by MidCap Financial SBIC, Oxford Finance and BB&amp;T Capital Partners and available
cash of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Merger
Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety
by, the full text of the Merger Agreement and Amendment No. 1 to the Merger Agreement, copies of which are attached hereto as Exhibits
2.1 and 2.2, respectively, and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 3.01</B></TD><TD STYLE="text-align: justify"><B>Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the Merger, on April
20, 2012, the Company submitted a written request to The NASDAQ Stock Market LLC (&ldquo;NASDAQ&rdquo;) for NASDAQ to cease trading
of the Company&rsquo;s common stock on the NASDAQ Capital Market, to suspend the listing of the Company&rsquo;s common stock and
to file with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) an application on Form 25 to delist the Company&rsquo;s
common stock from the NASDAQ Capital Market and deregister the Company&rsquo;s common stock under Section&nbsp;12(b) of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company intends to file with the SEC
a certification on Form 15, requesting the deregistration of the Company&rsquo;s common stock under Section&nbsp;12(g) of the Exchange
Act and the suspension of the Company&rsquo;s reporting obligations under Sections 13 and&nbsp;15(d) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 3.03</B></TD><TD STYLE="text-align: justify"><B>Material Modifications to Rights of Security Holders.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the effective time of the Merger, holders
of the Company&rsquo;s common stock, restricted stock and stock options immediately prior to such effective time ceased to have
any rights as stockholders of the Company (other than their right to receive the Per Share Merger Consideration or, in the case
of each outstanding stock option, the option consideration equal to the excess of $4.00 over the per share exercise price of such
option), and, accordingly, such holders no longer have any interest in the Company&rsquo;s future earnings or growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.01</B></TD><TD STYLE="text-align: justify"><B>Changes in Control of Registrant.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in Items&nbsp;2.01, 3.01
and 3.03 is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.02</B></TD><TD STYLE="text-align: justify"><B>Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the effective time of the Merger and
pursuant to the terms of the Merger Agreement, each of the directors of the Company was removed and the directors of Merger Sub
became the directors of the Company. The new directors of the Company are: Brian Miller and William Drehkoff. Messrs. Miller and
Drehkoff are affiliated with Linden.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the effective time of the Merger and
pursuant to the terms of the Merger Agreement, each of the officers of the Company (including Gregory Gould, the Interim President
and Chief Executive Officer, Chief Financial Officer and Treasurer) was removed and the officers of Merger Sub became the officers
of the Company. The new officers of the Company include: Charles Mamrak, Chief Executive Officer and President; and Harold Ingalls,
Chief Financial Officer and Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.03</B></TD><TD STYLE="text-align: justify"><B>Amendments to Articles of Incorporation or Bylaws;
Changes in Fiscal Year.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Merger Agreement, at the
effective time of the Merger, the Company&rsquo;s certificate of incorporation was amended and restated in its entirety as set
forth in Exhibit A to the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Merger Agreement, at the
effective time of the Merger, the Company&rsquo;s bylaws were amended and restated in their entirety as the bylaws of Merger Sub
in effect immediately prior to the effective time of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Copies of the amended and restated certificate
of incorporation and amended and restated bylaws of the Company are attached hereto as Exhibits 3.1 and 3.2, respectively, and
are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.07</B></TD><TD STYLE="text-align: justify"><B>Submission of Matters to a Vote of Security Holders.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 18, 2012, the Company held the
Special Meeting to adopt the Merger Agreement. Adoption of the Merger Agreement required the affirmative vote of the holders of
at least a majority of the shares of the Company&rsquo;s common stock outstanding at the close of business on March 12, 2012 (the
&ldquo;Record Date&rdquo;) and entitled to vote in accordance with Delaware law. According to the report of the inspector of elections,
the Merger Agreement was approved by the Company&rsquo;s stockholders at the Special Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A second proposal to approve, by a non-binding,
advisory vote, certain compensation arrangements for the Company&rsquo;s named executive officers in connection with the Merger
was also approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A third proposal to adjourn or postpone
the Special Meeting, if necessary, to solicit additional proxies in favor of adoption of the Merger Agreement was not needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The tally for the votes for the adoption
of the Merger Agreement is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="width: 60%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">for</FONT></P></TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">against</FONT></P></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">abstain</FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">13,587,071</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">2,021,331</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">3,294</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The tally for the votes for approval, by
a non-binding, advisory vote, of certain compensation arrangements for the Company&rsquo;s named executive officers in connection
with the Merger is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="width: 60%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">for</FONT></P></TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">against</FONT></P></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">abstain</FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">12,409,625</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">3,135,641</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">66,430</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 9.01</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) &#9;<U>Exhibits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; padding-right: 5.4pt; font-size: 10pt; font-weight: bold; text-decoration: underline">Exhibit No.</TD>
    <TD STYLE="width: 80%; padding-right: 5.4pt; font-size: 10pt; font-weight: bold; text-decoration: underline">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">2.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company&rsquo;s Current Report on Form 8-K, event date February 12, 2012, filed on February 14, 2012)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">2.2</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Amendment No. 1, dated February 27, 2012, to Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company&rsquo;s Current Report on Form 8-K, event date February 27, 2012, filed on February 28, 2012)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">3.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Amended and Restated Certificate of Incorporation of SeraCare Life Sciences, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">3.2</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Amended and Restated Bylaws of SeraCare Life Sciences, Inc.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"><B>SERACARE LIFE SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in">By: <U> &#9;/s/ Charles Mamrak&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Charles Mamrak</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">Title: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: April 24, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; padding-right: 5.4pt; font-size: 10pt; font-weight: bold; text-decoration: underline">Exhibit No.</TD>
    <TD STYLE="width: 80%; padding-right: 5.4pt; font-size: 10pt; font-weight: bold; text-decoration: underline">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">2.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company&rsquo;s Current Report on Form 8-K, event date February 12, 2012, filed on February 14, 2012)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">2.2</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Amendment No. 1, dated February 27, 2012, to Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company&rsquo;s Current Report on Form 8-K, event date February 27, 2012, filed on February 28, 2012)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">3.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Amended and Restated Certificate of Incorporation of SeraCare Life Sciences, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-right: 6.7pt; padding-bottom: 12pt; font-size: 10pt">3.2</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt">Amended and Restated Bylaws of SeraCare Life Sciences, Inc.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v310256_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 37771}]
{"company-data": {"conformed-name": "SERACARE LIFE SCIENCES INC", "cik": "0001156295", "assigned-sic": "2835", "irs-number": "330056054", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-34105", "film-number": "12776879"}, "business-address": {"street1": "37 BIRCH STREET", "city": "MILFORD", "state": "MA", "zip": "01757", "phone": "5082446400"}, "mail-address": {"street1": "37 BIRCH STREET", "city": "MILFORD", "state": "MA", "zip": "01757"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported):
April 18, 2012
SeraCare Life Sciences, Inc.
(Exact Name of Registrant as Specified
in Charter)
Delaware
001-34105
33-0056054
(State or other jurisdiction
of incorporation)
(Commission file number)
(IRS Employer
Identification No.)
37 Birch Street, Milford, Massachusetts
01757
(Address of principal executive offices)
Registrant's telephone number, including
area code:
(508) 244-6400
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.01
Completion of
Acquisition or Disposition of Assets.
At a special meeting of stockholders held
on April 18, 2012 (the "Special Meeting"), the stockholders of SeraCare Life Sciences, Inc., a Delaware corporation
(the "Company"), adopted the Agreement and Plan of Merger dated as of February 12, 2012 (as amended, the "Merger
Agreement") by and among the Company, Project Plasma Holdings Corporation, a Delaware corporation ("Parent"),
and Project Plasma Merger Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and
the merger contemplated thereby (the "Merger").
On April 20, 2012, the Company filed a certificate
of merger with the Secretary of State of the State of Delaware and completed the Merger, pursuant to which Merger Sub merged with
and into the Company, resulting in the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
Parent is controlled by private equity funds associated with Linden Capital Partners ("Linden").
As a result of the Merger, each share of
the Company's common stock issued and outstanding immediately prior to the effective time of the Merger (other than shares
(i) held by the Company in treasury, (ii) owned by Parent or Merger Sub or any other wholly owned subsidiary of Parent, or (iii)
held by stockholders who had perfected and not withdrawn a demand for appraisal rights under Delaware law) was cancelled and converted
automatically into the right to receive $4.00 in cash (the "Per Share Merger Consideration"), without interest. In
addition, at the effective time (a) each outstanding share of the Company's common stock subject to a risk of forfeiture
or a right of repurchase ("restricted stock") was vested in full and became free of such restrictions, and was cancelled
and extinguished and automatically converted into the right to receive the Per Share Merger Consideration, without interest, and
(b) each outstanding option to acquire the Company's common stock with an exercise price less than $4.00 per share was cancelled
and converted automatically into the right to receive an amount in cash equal to the excess of $4.00 over the per share exercise
price of the stock option, for each share for which the option would have been exercisable. The total amount of the consideration
payable in connection with the Merger, including with respect to restricted stock and stock options, is approximately $82.1 million
in cash. The funds used by Parent to consummate the Merger are from equity contributions by private equity funds affiliated with
Linden, proceeds from debt financing provided by MidCap Financial SBIC, Oxford Finance and BB&T Capital Partners and available
cash of the Company.
The foregoing description of the Merger
Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety
by, the full text of the Merger Agreement and Amendment No. 1 to the Merger Agreement, copies of which are attached hereto as Exhibits
2.1 and 2.2, respectively, and are incorporated herein by reference.
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
In connection with the Merger, on April
20, 2012, the Company submitted a written request to The NASDAQ Stock Market LLC ("NASDAQ") for NASDAQ to cease trading
of the Company's common stock on the NASDAQ Capital Market, to suspend the listing of the Company's common stock and
to file with the Securities and Exchange Commission (the "SEC") an application on Form 25 to delist the Company's
common stock from the NASDAQ Capital Market and deregister the Company's common stock under Section 12(b) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act").
The Company intends to file with the SEC
a certification on Form 15, requesting the deregistration of the Company's common stock under Section 12(g) of the Exchange
Act and the suspension of the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act.
Item 3.03
Material Modifications to Rights of Security Holders.
Upon the effective time of the Merger, holders
of the Company's common stock, restricted stock and stock options immediately prior to such effective time ceased to have
any rights as stockholders of the Company (other than their right to receive the Per Share Merger Consideration or, in the case
of each outstanding stock option, the option consideration equal to the excess of $4.00 over the per share exercise price of such
option), and, accordingly, such holders no longer have any interest in the Company's future earnings or growth.
Item 5.01
Changes in Control of Registrant.
The information in Items 2.01, 3.01
and 3.03 is incorporated herein by reference.
Item 5.02
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Upon the effective time of the Merger and
pursuant to the terms of the Merger Agreement, each of the directors of the Company was removed and the directors of Merger Sub
became the directors of the Company. The new directors of the Company are: Brian Miller and William Drehkoff. Messrs. Miller and
Drehkoff are affiliated with Linden.
Upon the effective time of the Merger and
pursuant to the terms of the Merger Agreement, each of the officers of the Company (including Gregory Gould, the Interim President
and Chief Executive Officer, Chief Financial Officer and Treasurer) was removed and the officers of Merger Sub became the officers
of the Company. The new officers of the Company include: Charles Mamrak, Chief Executive Officer and President; and Harold Ingalls,
Chief Financial Officer and Secretary.
Item 5.03
Amendments to Articles of Incorporation or Bylaws;
Changes in Fiscal Year.
Pursuant to the Merger Agreement, at the
effective time of the Merger, the Company's certificate of incorporation was amended and restated in its entirety as set
forth in Exhibit A to the Merger Agreement.
Pursuant to the Merger Agreement, at the
effective time of the Merger, the Company's bylaws were amended and restated in their entirety as the bylaws of Merger Sub
in effect immediately prior to the effective time of the Merger.
Copies of the amended and restated certificate
of incorporation and amended and restated bylaws of the Company are attached hereto as Exhibits 3.1 and 3.2, respectively, and
are incorporated herein by reference.
Item 5.07
Submission of Matters to a Vote of Security Holders.
On April 18, 2012, the Company held the
Special Meeting to adopt the Merger Agreement. Adoption of the Merger Agreement required the affirmative vote of the holders of
at least a majority of the shares of the Company's common stock outstanding at the close of business on March 12, 2012 (the
"Record Date") and entitled to vote in accordance with Delaware law. According to the report of the inspector of elections,
the Merger Agreement was approved by the Company's stockholders at the Special Meeting.
A second proposal to approve, by a non-binding,
advisory vote, certain compensation arrangements for the Company's named executive officers in connection with the Merger
was also approved.
A third proposal to adjourn or postpone
the Special Meeting, if necessary, to solicit additional proxies in favor of adoption of the Merger Agreement was not needed.
The tally for the votes for the adoption
of the Merger Agreement is as follows:
for
against
abstain
13,587,071
2,021,331
3,294
The tally for the votes for approval, by
a non-binding, advisory vote, of certain compensation arrangements for the Company's named executive officers in connection
with the Merger is as follows:
for
against
abstain
12,409,625
3,135,641
66,430
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
.
Exhibit No.
Description
2.1
Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company's Current Report on Form 8-K, event date February 12, 2012, filed on February 14, 2012)
2.2
Amendment No. 1, dated February 27, 2012, to Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company's Current Report on Form 8-K, event date February 27, 2012, filed on February 28, 2012)
3.1
Amended and Restated Certificate of Incorporation of SeraCare Life Sciences, Inc.
3.2
Amended and Restated Bylaws of SeraCare Life Sciences, Inc.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SERACARE LIFE SCIENCES, INC.
By:
/s/ Charles Mamrak
Name:     Charles Mamrak
Title: Chief Executive Officer
Dated: April 24, 2012
EXHIBIT INDEX
Exhibit No.
Description
2.1
Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company's Current Report on Form 8-K, event date February 12, 2012, filed on February 14, 2012)
2.2
Amendment No. 1, dated February 27, 2012, to Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company's Current Report on Form 8-K, event date February 27, 2012, filed on February 28, 2012)
3.1
Amended and Restated Certificate of Incorporation of SeraCare Life Sciences, Inc.
3.2
Amended and Restated Bylaws of SeraCare Life Sciences, Inc.